Page last updated: 2024-11-12

etimicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

etimicin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

etimicin : An aminoglycoside antibiotic that is gentamycin C1a in which the hydrogen of the amino group at position 1 is substituted by an ethyl group. It is a fourth generation semisynthetic aminoglycoside that has antimicrobial activity against both gram-positive and gram-negative bacterial infections and also effective against aminoglycoside resistant strains. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9912913
CHEBI ID134705
MeSH IDM0416710

Synonyms (17)

Synonym
59711-96-5
CHEBI:134705
etilmicin
1-n-ethylgentamicin c1a
antibiotic 89-07
n(1)-ethylgentamicin c1a
etimicin
(1r,2s,3s,4r,6s)-6-amino-3-{[3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl]oxy}-4-(ethylamino)-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranoside
d-streptamine, o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1->6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1->4))-2-deoxy-n1-ethyl-
8ics2wxt2k ,
n1-ethylgentamicin c1a
unii-8ics2wxt2k
etimicin [who-dd]
d-streptamine, o-3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-.alpha.-d-erythro-hexopyranosyl-(1->4))-2-deoxy-n1-ethyl-
(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4-amino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
Q27270580
DTXSID201318731

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In the present study, we compared the in vivo toxic effects of three aminoglycosides, gentamicin, amikacin, and etimicin, in zebrafish embryos."( A new aminoglycoside etimicin shows low nephrotoxicity and ototoxicity in zebrafish embryos.
Chen, D; Han, Y; Jiang, H; Jing, L; Li, R; Qian, X; Shao, W; Yin, Y; Zhong, D, 2021
)
1.15

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic para-meters were determined from serum concentration-time data with the 3p87-software package."( Influence of piperacillin on pharmacokinetics of etimicin in healthy volunteers.
Ma, TX; Ma, XC; Wang, HX; Zhang, LR, 2002
)
0.57
" In the present study we compared the antibacterial and toxicity profiles of etimicin, gentamicin (GM, a second-generation AG), and amikacin (AMK, a third-generation AG), and investigated their pharmacokinetic properties in the toxicity target organs (kidney and inner ear) and subcellular compartments."( Mechanisms and pharmacokinetic/pharmacodynamic profiles underlying the low nephrotoxicity and ototoxicity of etimicin.
Cai, MM; Chen, B; Feng, D; Sun, JG; Wang, GJ; Wang, QZ; Wang, XY; Yao, L; Zhang, JW; Zheng, YW; Zhou, F, 2020
)
1

Dosage Studied

ExcerptRelevanceReference
" No modification in dosing regimen is necessary when two drugs were co-administered."( Influence of piperacillin on pharmacokinetics of etimicin in healthy volunteers.
Ma, TX; Ma, XC; Wang, HX; Zhang, LR, 2002
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminoglycoside antibiotic
amino cyclitol glycoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's6 (54.55)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.21 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index50.74 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (15.38%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (7.69%)4.05%
Observational0 (0.00%)0.25%
Other10 (76.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]